Cardiotoxicity Associated With Pediatric Hodgkin Lymphoma Treatment

Introduction: Cardiotoxicity is one of the possible consequences of treating Hodgkin's lymphoma. This assumes a very important role in the patients outcomes since, increasingly, theyhave a higher survival rate, better quality of life and inherently longer survival. This is due to the improvement in the treatment of this pathology.Material and methods: Clinical information was collected from 103 patients about their age at diagnosis, sex, cardiovascular risk factors, anthracycline dose to which they were subjected and the use of mediastinal radiotherapy.According to this information, echocardiograms of these patients were analysed at five different times. Results: We obtained lower TAPSE values for females and for higher doses. Inverse relationships were also observed between the TAPSE value measured 6 months after treatment. The LV systolic function 5 years after treatment was inversed relationed with the age of the patients. Discussion: It was observed that there may be a relationship between the TAPSE 3 values and the anthracycline dose to which the patient was submitted, and we found lower TAPSE values in the group with the highest dose, in this case of 220 mg/m2.Conclusion: The incidence of cardiotoxicity after treatment for Hodgkin's lymphoma was 8% in the studied population.One of the conclusions we can take from this study is that it appears that cardiac toxic cardiac toxicity begins to reflect on right heart function in a chronic phase, more than 2 years after treatment.Other conclusions we can draw are that younger age, female sex and higher cumulative dose could be risk factors for cardiotoxicity due to anthracyclines.